ZA200405290B - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase (serine/threonine kinase) inhibitors. - Google Patents

Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase (serine/threonine kinase) inhibitors.

Info

Publication number
ZA200405290B
ZA200405290B ZA200405290A ZA200405290A ZA200405290B ZA 200405290 B ZA200405290 B ZA 200405290B ZA 200405290 A ZA200405290 A ZA 200405290A ZA 200405290 A ZA200405290 A ZA 200405290A ZA 200405290 B ZA200405290 B ZA 200405290B
Authority
ZA
South Africa
Prior art keywords
serine
threonine kinase
kinase
inhibitors
distamycin derivatives
Prior art date
Application number
ZA200405290A
Other languages
English (en)
Inventor
Maria Geroni
Camilla Fowst
Paolo Cozzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of ZA200405290B publication Critical patent/ZA200405290B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA200405290A 2002-01-02 2004-07-02 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase (serine/threonine kinase) inhibitors. ZA200405290B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02075052 2002-01-02

Publications (1)

Publication Number Publication Date
ZA200405290B true ZA200405290B (en) 2005-06-17

Family

ID=8185508

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200405290A ZA200405290B (en) 2002-01-02 2004-07-02 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase (serine/threonine kinase) inhibitors.

Country Status (24)

Country Link
US (1) US20060084612A1 (xx)
EP (1) EP1461083B1 (xx)
JP (1) JP2005516025A (xx)
KR (1) KR20040078118A (xx)
CN (1) CN1617744A (xx)
AT (1) ATE321572T1 (xx)
AU (1) AU2002352090B8 (xx)
BR (1) BR0215454A (xx)
CA (1) CA2472008C (xx)
CY (1) CY1105269T1 (xx)
DE (1) DE60210329T2 (xx)
DK (1) DK1461083T3 (xx)
ES (1) ES2263835T3 (xx)
HU (1) HUP0402639A3 (xx)
IL (2) IL162820A0 (xx)
MX (1) MXPA04006543A (xx)
NO (1) NO20043217L (xx)
NZ (1) NZ533854A (xx)
PL (1) PL371179A1 (xx)
PT (1) PT1461083E (xx)
RU (1) RU2328306C2 (xx)
SI (1) SI1461083T1 (xx)
WO (1) WO2003055522A1 (xx)
ZA (1) ZA200405290B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
PT1545553E (pt) * 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
WO2006108763A1 (en) * 2005-04-08 2006-10-19 Nerviano Medical Sciences S.R.L. Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274576B1 (en) * 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors

Also Published As

Publication number Publication date
CN1617744A (zh) 2005-05-18
KR20040078118A (ko) 2004-09-08
RU2328306C2 (ru) 2008-07-10
WO2003055522A1 (en) 2003-07-10
DK1461083T3 (da) 2006-07-10
DE60210329D1 (de) 2006-05-18
RU2004123641A (ru) 2005-06-10
AU2002352090B8 (en) 2008-06-19
SI1461083T1 (sl) 2006-08-31
IL162820A (en) 2010-04-15
EP1461083B1 (en) 2006-03-29
HUP0402639A3 (en) 2012-02-28
PT1461083E (pt) 2006-08-31
CA2472008C (en) 2009-07-28
AU2002352090A1 (en) 2003-07-15
ES2263835T3 (es) 2006-12-16
NO20043217L (no) 2004-07-30
DE60210329T2 (de) 2006-11-30
IL162820A0 (en) 2005-11-20
JP2005516025A (ja) 2005-06-02
MXPA04006543A (es) 2004-10-04
CY1105269T1 (el) 2010-03-03
BR0215454A (pt) 2004-11-23
US20060084612A1 (en) 2006-04-20
HUP0402639A2 (hu) 2005-04-28
EP1461083A1 (en) 2004-09-29
NZ533854A (en) 2007-05-31
PL371179A1 (en) 2005-06-13
AU2002352090B2 (en) 2008-05-15
ATE321572T1 (de) 2006-04-15
CA2472008A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
DE60204553D1 (de) Jun kinase inhibitoren
YU84603A (sh) Novi inhibitori tirozin kinaze
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
WO2004096795A3 (en) C-fms kinase inhibitors
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
AU7846301A (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
CY1105269T1 (el) Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)
MXPA03004023A (es) Compuestos quimicos.
MXPA02012209A (es) Terapia combinada contra tumores que comprende derivados de bistamicina acriloilo substituida y agentes de alquilacion.
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
MXPA02012165A (es) Terapia combinada contra tumores que comprende derivados de acriloil-distamicina sustituida, taxanos y/o antimetabolitos.
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ